Kornimate/medical-research-clean huggingface dataset:
anti-mullerian hormone,testesterone,esrtadiol,testesterone/esrtadiol ratio as predictive values for tesa and tese outcome in non obstructive azoospermia

Conditions: Non-obstructive Azoospermia

Summary: \*evaluate the predictive value of amh, testosterone,estradiol,testosterone estradiol ratio for tesa and tese outcome in non obstructive azoospermic patients.

* the relevance of male infertility has progressively grown , with significant medical, psychological, and socio-economic implications. .. with no sperm found at multiple semen analyses, non-obstructive azoospermia (noa) is the most severe form of infertility. * the introduction to clinical practice of assisted reproduction techniques such as intra-cytoplasmic sperm injection (icsi) made fatherhood possible for men with (noa). the extraction of sperm from the testis through testicular sperm aspiration (tesa), testicular sperm extraction (tese) or open biopsy can result in a favorable reproductive outcome. nevertheless, all these procedures are invasive in nature with variable possibility of successful sperm extraction. as a consequence, a non-invasive test that could predict the presence of sperm in men with noa would be of profound clinical importance * however, the lack of useful predictive biomarkers suggestive for successful sperm retrieval at microtese and tesa in noa men still represents a relevant gap with a very negative return for the patient. indeed, no significant association has been found between microteseand tesa sperm retrieval outcomes and preoperative testicular volume, baseline follicular stimulating hormone (fsh) levels, basal level of testosterone (t) or increased t level following treatments with aromatase inhibitors, clomiphene citrate or human chorionic gonadotropin. * therefore, it has been amust to identify novel and user-friendly prognostic factors reliably predicting surgical outcomes in noa men in the real-life setting. among other variables, some hormons can be subjected to studies for this purpose such as levels of testis-derived hormones (which might be representative of the primary testicular failure) as the anti-müllerian hormone (amh),( which is suggestive for a sertoli cells' immature phenotype),and testosterone of biological relevance... * an investigation from the early 1970s demonstrated that the human testis does indeed secrete estradiol within the spermatic vein, at amean concentration that is 50 times greater than that inthe peripheral plasma . these findings led to the hypothesis that local estrogen levels might be associated with the current stateof spermatogenesis, or the total number of spermatogenic cells in the testis.

Eligibility criteria:
inclusion criteria: * a clinical diagnosis of noa associated with primary couple's infertility; * age from 20 to 50 years old * freedom from any known systemic diseases affecting the previous hormonal levels such as liver cirrhosis . * hormonal therapy for at least two weeks prior to the surgery exclusion criteria: * obstructive azoospermia * congenital bilateral absent vas
fibrinogen to albumin ratio and c-reactive protein to albumin ratio in juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis

Summary: the fibrinogen to albumin ratio (far) and c-reactive protein to albumin ratio (car) have emerged as useful biomarkers to predict systemic inflammation. the aim here is to investigate the relation between far/car and juvenile arthritis disease activity score (jasdas27) in juvenile idiopathic arthritis (jia)

the jadas27 includes a selected count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal interphalangeal joints, hips, knees and ankles.

Eligibility criteria:
inclusion criteria: * all juvenile idiopathic arthritis fulfilling the criteria of international league of associations for rheumatology (ilar) and age and sex matched healthy subjects exclusion criteria: * other systemic inflammatory or autoimmune disorders. * history of corticosteroid medication in the last 6 months. * liver diseases. * malignancy.
investigation of the effectiveness of neuromuscular exercise program accompanied with degenerative meniscal tear

Conditions: Meniscus Tear; Knee Injuries

Summary: the aim of the study was to investigate the effect of exercise program added to the treatment on physical function, postural balance, muscle strength, pain and gait in individuals with meniscal damage.


Eligibility criteria:
inclusion criteria: * age between 20-65 years. * having a meniscus tear. * volunteering to participate in the study. exclusion criteria: * being diagnosed with a psychiatric illness. * having a neurological disease that may interfere with treatment. * having undergone meniscal surgery before. * having received physical therapy in the knee area in the last 6 months. * benefiting from any other treatment during the study.

Keywords: knee
safety and efficacy of prochymal® for the salvage of treatment-refractory acute gvhd patients

Conditions: Graft Versus Host Disease

Summary: this study is designed to evaluate the safety and efficacy of prochymal® (ex-vivo cultured adult human mesenchymal stem cells) in participants experiencing treatment-refractory acute gvhd, grades iii-iv, that is refractory to standard first-line therapies and at least one second-line therapy.

allogeneic hematopoetic stem cell transplantation (hct) is used in the treatment of a variety of hematological, myeloproliferative and lymphoproliferative disorders, and malignancies involving solid tumors. patients receiving hct can develop a life-threatening condition called graft versus host disease (gvhd). gvhd occurs when donor t cells from the donor bone marrow recognize host cells as "foreign" and initiate an inflammatory immunological response. the standard of care for treatment of acute gvhd consists of intravenous delivery of methylprednisolone starting on day 1 and continuation of either cyclosporine or tacrolimus. this regimen of steroids and immunosuppressive drugs may relieve symptoms of gvhd, but some patients are refractory to current standard of care treatment. for treatment-refractory patients with grades iii-iv gvhd mortality is approximately 80%. a therapy that could effectively suppress the immunological response from gvhd and help repair the damaged tissue could significantly decrease the mortality rate from this disease.

Eligibility criteria:
inclusion criteria: * participants must be 6 months to 70 years of age inclusive. * if female and of childbearing age, participants must be non-pregnant, not breast-feeding, and use adequate contraception. male participants must use adequate contraception. * participants must have grade iii-iv acute gvhd that has failed to respond to standard first and at least one second-line therapy. biopsy for confirmation of both skin and gastrointestinal gvhd is not mandatory, but is recommended when feasible. enrollment should not be delayed awaiting biopsy results. * participants must have minimal renal function as defined by: calculated creatinine clearance (crcl) of \> 30 milliliters/minute (ml/min) using the cockcroft-gault equation. * participants must provide written informed consent and authorization for use and disclosure of protected health information (phi). exclusion criteria: * participant has uncontrolled alcohol or substance abuse within 6 months of treatment. * participant has any underlying or current medical or psychiatric condition that, in the opinion of the investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.). * participant has a clinically significant, unstable arrhythmia. * participant has a known allergy to bovine or porcine products. * participant is unwilling to sign consent form for the long-term follow-up study, protocol 271.

Keywords: gvhd graft vs host disease graft versus host disease
mechanism of perk - eif2a pathways in intestinal mucosal barrier of ibs-d and the role "metabolism ingredients" of tongxieyaofang

Conditions: IBS (Irritable Bowel Syndrome)

Summary: diarrhea irritable bowel syndrome(ibs-d）has seriously affected health and quality of life of patients.it may be important pathogenesis in development and recurrence of the process of ibs-d,excessive endoplasmic reticulum stress (ers) activated perk(proteinkinaser-like erkinase，perk)-eif2a(eukaryotic translation initiation factor 2 alpha,eif2a) pathway and damaged intestinal mucosal epithelial barrier. tongxieyaofang(txyf) had obtained satisfactory effect in treating ibs-d in clinic and previous study, but it is unknown that herbal formula how to work.this project applies metabolomics method to detect plasma,urine and stool metabolites for patients before and after treatment, to determine the effects of the"multiple ingredients"of txyf in body.


Eligibility criteria:
inclusion criteria: * patients meeting the diagnostic criteria of western medicine for ibs-d; * aged 18-70 years old; with a baseline ibs-sss score over 75 points; * voluntarily signed the informed consent; * local resident who could ensure follow-ups, with basic reading ability exclusion criteria: * patients with ibs-c, -m, and uncertain forms; * accompanied with serious lesions in major organs including heart, liver, and kidney, hematopoietic system diseases, and tumors; * gastrointestinal organic disease (e.g., chronic pancreatitis), or systemic diseases affecting the digestive tract motion (e.g., hyperthyroidism,diabetes, chronic renal insufficiency, and nervous system diseases); * undergoing or requiring constant use of drugs that may affect gastrointestinal functions (e.g., anti-cholinergic drugs, calcium channel blockers, 5-ht3 receptor antagonist, antidiarrheal agents, antacids, prokinetic agents, antidepressants, anxiolytics, and intestinal flora regulating drugs); * with history of abdominal surgery (e.g., cholecystectomy); * with an allergy history of tested drugs or severe allergy history of food; * pregnant and lactating female; * with a history of neurological or psychiatric disorders; * or participating in other clinical trial.

Keywords: ibs-d
effects of gum chewing on recovery of bowel function following abdominal surgery for endometrial and ovarian cancer

Conditions: Paralytic Ileus

Summary: following extensive abdominal surgery for the treatment of endometrial or ovarian cancer, paralytic ileus frequently develops. gum chewing can promotes the return of bowel function through the cephalic-vagal reflex and increased intestinal enzymes secretion. the objectives of this study are to evaluate effects of adding gum chewing to the conventional postoperative feeding protocol on the return of bowel function, its related complications, and patients' satisfaction.


Eligibility criteria:
inclusion criteria: * patients undergoing staging or cytoreductive surgery for primary endometrial or ovarian cancer at maharaj nakorn chiang mai hospital exclusion criteria: * perioperative hyperalimentation * recent chemotherapy (within 3 weeks before surgery) * previous bowel surgery * inflammatory bowel diseases * previous abdominal or pelvic radiation * need for immediate postoperative endotracheal intubation * need for postoperative admission to intensive care unit * undergoing emergency surgery with oral intake of fluid or food within 4 hours before surgery
magnesium supplementation in simultaneous pancreas-kidney transplantation

Conditions: Renal Failure Chronic Requiring Dialysis; Diabetes Mellitus, with Complications; Glomerulosclerosis; Pancreatic Insufficiency (Exocrine and Endocrine); Transplantation, Kidney; Pancreas Transplantation

Summary: magnesium is essential in human physiology. simultaneous pancreas-kidney (spk) transplant recipients frequently experience hypomagnesemia. the effects of hypomagnesaemia are harmful. this observational study assessed intraoperative magnesium supplementation's utility in patients undergoing spk transplantation. perioperative hemodynamics were monitored. postoperative serum magnesium was monitored at 12 hours and 48 hours.

a vital component of human physiology is magnesium. it is common for recipients of simultaneous pancreas-kidney (spk) transplants to have hypomagnesemia. the consequences of hypomagnesaemia are detrimental. this prospective observational study evaluated the effectiveness and safety of intraoperative magnesium supplementation in adult spk transplant recipients. arrhythmia and perioperative hemodynamics were observed. serum magnesium levels were checked 12 and 48 hours after surgery.

Eligibility criteria:
inclusion criteria: * adult diabetic patients who require insulin therapy and hemodialysis due to pancreatic-kidney failure. exclusion criteria: * adult diabetic patients who do not require insulin therapy and hemodialysis.

Keywords: spk transplant simultaneous pancreas-kidney (spk) transplant hypomagnesemia transplantation hypomagnesemia kidney transplant hypomagnesemia pancreas-kidney transplant hypomagnesemia simultaneous pancreas-kidney transplant
effect of different oxygen concentration on postoperative pulmonary complications after pulmonary reexpansion

Conditions: Pulmonary Disease

Summary: to evaluate the effect of 80% inspiratory oxygen fraction (fio2) and 30% fio2 on the incidence of pulmonary complications after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative within the first 7 days after thoracic surgery, based on lung protective ventilation strategy.

postoperative pulmonary complications (ppcs) account for the highest proportion (about 84%) among all the factors leading to death in thoracic surgery. high fio2 was used in perioperative period. however, there is increasing evidence that high fio2 in non-thoracic surgery can increase respiratory related adverse events and even mortality. the guideline also suggests that low fio2 (30-50%) during surgery while ensuring moderate level of oxygenation would be more beneficial to the prognosis of patients. whereas, the selection of oxygen concentration in thoracic surgery is still unclear, especially which oxygen concentration ventilation is more beneficial to reduce ppcs after pulmonary reexpansion. strict randomized controlled clinical studies are urgently needed to verify the differences in the incidence of ppcs in patients with different oxygen concentration ventilation strategies. the study aim is to evaluate the effect of 80% fio2 and 30% fio2 on the incidence of pulmonary complications after pulmonary reexpansion following one-lung ventilation and 2-hour postoperative within the first 7 days after thoracic surgery, based on lung protective ventilation strategy, and to provide clinical basis for optimizing perioperative management of thoracic surgery and effectively reducing the occurrence of perioperative pulmonary complications

Eligibility criteria:
inclusion criteria:1. elective thoracic surgery: lung surgery, esophageal surgery, mediastinal surgery, etc.; 2. one-lung ventilation: double lumen bronchial cannula or occluder is used for isolation of one lung; 3, american society of anesthesiology (asa) grade i \~ iii; 4, 18 years ≤ age \< 80 years; 5. estimated operation time ≥2 hours; 6. agree to participate and sign the informed consent. exclusion criteria: 1. severe lung infection occurs within 1 month; 2. coronary heart disease or heart failure occurs within 2 or 3 months; 3. preoperative oxygen saturation is less than 94%; 4, need continuous oxygen therapy; 5, bmi\>35 kg/m2; 6. pregnant women; 7. preoperative hb\<70g/l or haematocrit\<30%.

Keywords: postoperative pulmonary complications thoracic surgery inspiratory oxygen fraction
the use of probiotics to evaluate colonization with antimicrobial resistant bacteria

Conditions: Infectious Disease of Digestive Tract

Summary: the purpose of this study is to evaluate the effectiveness of bacteria called lactobacillus gg, a probiotic, in preventing the growth of resistant bacteria in the digestive tract in patients on a ventilator.


Eligibility criteria:
inclusion criteria: * adults ≥ 18 years old * admission to the medical icu * expected to be on mechanical ventilation through an endotracheal tube for \>48 hours exclusion criteria: * pregnancy * immunosuppression * prosthetic valve or vascular graft * cardiac trauma * pancreatitis * history of rheumatic fever * endocarditis or congenital cardiac abnormality * gastroesophageal or intestinal injury or foregut surgery during the current admission * oropharyngeal mucosal injury * placement of a tracheostomy

Keywords: probiotics
assessment of portable oxygen concentrators in infants undergoing hypoxic challenge testing.

Conditions: Hypoxia, Altitude

Summary: hypoxic challenge testing (hct) is the recommended method for inflight hypoxia risk assessment. onboard oxygen administration remains controversial. the federal aviation administration approved portable oxygen concentrators (pocs) for onboard oxygen supply but there is lack of evidence about the use, especially in children. the aim of our study is to establish the effectiveness and safety of pocs in infants undergoing hct.

according to a forecast by international air transport association the number of people travelling on commercial aircrafts is predicted to rise up to 8.2 billion passengers in 2037. therefore evidence-based flight recommendations will gain importance in the future, especially for patients suffering from chronic diseases. hypoxic challenge testing (hct) is the recommended method for inflight hypoxia risk assessment where nitrogen is introduced in a plethysmograph reducing fio2 (fraction of inspired oxygen) to 0.15. oxygen supply is recommended if pao2 (partial pressure of oxygen in arterial blood) drops \<50-55 mmhg (in adults) or sat.o2 (oxygen saturation) ≤ 85% (in infants) where non-invasive pulse oximetry is the recommended method for hypoxia assessment. onboard oxygen administration remains controversial. the effectiveness of pulsed-dosed systems remains unclear in small patients due to shallow breathing patterns. the aim of our study is to establish the effectiveness and safety of pocs in infants undergoing hct.

Eligibility criteria:
inclusion criteria: patients with baseline sat.o2 \>94% and * \<1 year with neonatal respiratory disease * required oxygen supply in the last 6 months * chronic respiratory disease (eg cystic fibrosis, obstructive or restrictive pulmonary disease) with fev 1 (forced expiratory volume in 1 second) or fvc (forced vital capacity) \<50%. exclusion criteria: * acute respiratory infection

Keywords: infants hypoxia altitude simulation test oxygen delivery device portable oxygen concentrator hypoxic challenge testing
effect of removal of intracanal medication on post operative pain

Conditions: Effects of the Elements

Summary: recruited patients with necrotic pulp after application of calcium hydroxide are assigned to group (xp endo finisher file) and group( passive ultrasonic irrigation) and group (conventional syringe irrigation with side vented needle) to remove intracanal medication and record postoperative pain afterwards.

the investigator will recruit patients who are found eligible to the criteria, calcium hydroxide will be inserted inside the canals. after 7 days, patients will be randomly assigned to either removal of intracanal medication using, the xp-endo finisher file, passive ultrasonic irrigation (pui) and conventional syringe irrigation with side vented needle. after the visit, patients will be asked to record post operative pain by visual analog scale)in a given sheet

Eligibility criteria:
inclusion criteria: * medically free patients. * patient's age between 20-50 years. * both sexes. * necrotic pulp as indicated by thermal or electric pulp testing. * no history of previous endodontic treatment of the tooth. * enough crown structure for adequate isolation. exclusion criteria: * pregnancy or lactation * medically compromised patients * previous endodontic therapy of the affected tooth. * teeth diagnosed with vital pulp. * teeth with periodontal pocket more than 3mm deep. * teeth with abnormal anatomy or calcified canals. * teeth with caries below the bony level (non-restorable tooth). * immature teeth with open apices.
efficacy of two onabotulinum toxin doses

Conditions: Neurogenic Bladder; Overactive Detrusor

Summary: the changes in bladder function after the injection of onabotulinum toxin into the detrusor in individuals with neurogenic bladder overactivity will be investigated retrospectively. the records of all patients treated with onabotulinum toxin injections into the detrusor since 2000 will be evaluated. the changes in the urodynamic values after the injection of 300 units of onabotulinum toxin will be compared with the changes after the injection of 200 units. furthermore, the differences in urinary continence, duration between injections, side effects and complications between the two groups will be investigated.


Eligibility criteria:
inclusion criteria: * neurogenic detrusor overactivity * spinal cord injury * onabotulinum toxin injections into the detrusor from 2000-2017 exclusion criteria: * missing urodynamic values before or after onabotulinum toxin injections
cancers treated with combination of antrodia cinnamomea and chemotherapy

Conditions: Neoplasm; Functional Gastrointestinal Disorder

Summary: the purpose of this study is to investigate if food supplements,antrodia cinnamomea, could minimize the gastrointestinal symptom of cancer patients with chemotherapy.

in our unpublished report shows that patients who took antrodia cinnamomea compound of 15 milliliters liquid twice in a day, might help white blood cells, red blood cells and hemoglobin increase after 2 months; liver glutamic pyruvic transaminase(gpt) index mitigation, p \<0.05 difference statistically; in addition, liver glutamate oxaloacetate transaminase(got) and biochemical index of renal function had no abnormal data statistically. however, cancer patients with gastrointestinal disorders after chemotherapy is known to be a common side effect, we seek to investigate if antrodia cinnamomea improves the function of gastrointestinal system.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed cancer. * age ≦ 80 years old and ≧ 18 years old. * eastern cooperative oncology group(ecog) performance status of 0-2. * adequate organ function, including followings hepatic： total bilirubin level ≦1.5 x unl, got and gpt ≦ 2.5 x unl if no liver metastasis; got and gpt ≦ 5 x unl if liver metastasis. renal： creatinine level\< 1.5 milligram per deciliter or estimated creatinine clearance(ccr) ≧ 60 milliliter per minute (ccr is estimated by cockcroft-gault formula, as appendix ii) * estimated life expectancy of at least 12 weeks. * written(signed) informed consent * ever treated and poor tolerance with platinum-based or anthracycline- based regimen, likely nausea and vomiting. exclusion criteria: * prior participation in any investigational drug study within 28 days * active uncontrolled infections or human immunodeficiency virus(hiv) infection * significant concurrent medical diseases, such as congestive heart failure, unstable angina, acute or recent myocardial infarction( 6 months before randomization), chronic obstructive pulmonary disease with frequent exacerbation, chronic renal diseases (estimated ccr 60 milliliter per minute), uncontrolled diabetes, uncontrolled hypertension, recent cerebrovascular disease episode( 6 months before randomization ) * with clinically significant gastrointestinal disorder (e.g. bleeding, inflammation, obstruction or diarrhea) * psychiatric disorders that would compromise the patient's compliance or decision. * pregnancy or breast feeding. * known hypersensitivity to the component of investigational drugs. * known or suspected gilbert's syndrome * poor compliance

Keywords: cancers antrodia cinnamomea chemotherapy gastrointestinal disorder